Loading organizations...
§ Private Profile · Cambridge, MA, USA
Diagnostic platform developer offering portable point-of-care tests for HIV, HCV, and sickle cell disease in low-resource settings.
Based in Cambridge, Massachusetts, Daktari Diagnostics develops portable point-of-care diagnostic platforms and cloud-based data management systems for global health applications. The company focuses on engineering and manufacturing accessible testing solutions for infectious and non-communicable conditions, including HIV, Hepatitis C, and sickle cell disease, primarily targeting remote and low-resource medical settings across Africa. To support these initiatives, the enterprise has secured $73.42 million in total equity funding across 15 financing rounds from institutional backers such as the Merck Global Health Innovation Fund, the National Institutes of Health, the Department of Health and Human Services, and Norwich Investors. Operating with a workforce of 23 employees as of December 2022, the firm utilizes wireless connectivity to integrate remote diagnostic results directly into centralized electronic healthcare databases. Daktari Diagnostics was founded in 2008 by Bill Rodriguez and Mehmet Toner.
Daktari Diagnostics has raised $35.6M across 5 funding rounds.
Daktari Diagnostics has raised $35.6M in total across 5 funding rounds.
Daktari Diagnostics has raised $35.6M across 5 funding rounds. Most recently, it raised $1.3M Grant in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 5, 2016 | $1.3M Grant | National Institutes OF Health | — | Announced |
| Mar 2, 2015 | $15.5M Series D | Eastern Capital, Merck | Norwich Ventures, Partners Group | Announced |
| May 13, 2013 | $7M Venture Round | — | — | Announced |
| Dec 30, 2011 | $10M Venture Round | Merck | Norwich Ventures, Partners Innovation Fund | Announced |
| Nov 8, 2010 | $1.8M Venture Round | — | — | Announced |
Daktari Diagnostics has raised $35.6M in total across 5 funding rounds.
Daktari Diagnostics's investors include National Institutes of Health, Eastern Capital, Merck, Norwich Ventures, Partners Group, Partners Innovation Fund.